INCREASED THROMBOEMBOLIC RISK OF JAK INHIBITORS AFTER SWITCHING FROM BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Eun, Y. [1 ]
Seo, G. H. [2 ]
Kang, S. Y. [3 ]
Lee, S. [3 ]
Kim, H. [3 ,4 ]
Cha, H. S. [3 ]
Koh, E. M. [3 ]
Lee, J. [3 ]
机构：
[1] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Med, Sch Med, Seoul, South Korea
[2] Hlth Insurance Review & Assessment Serv, Wonju, South Korea
[3] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Dept Med Humanities, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.4952
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0418
引用
收藏
页码：1337 / 1337
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF JAK-INHIBITORS VERSUS BIOLOGIC DMARDS ON QUALITY OF LIFE IN RHEUMATOID ARTHRITIS : A META ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Boudhabhay, Mamadaly
    Barnetche, Thomas
    Vergne-Salle, Pascale
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 741 - 741
  • [22] Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al
    Rosenzwajg, Michelle
    Lorenzon, Roberta
    Klatzmann, David
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (12) : E197 - E197
  • [23] THE COST-EFFECTIVENESS OF BIOLOGIC DMARDS IN PATIENTS WITH SEVERE OR MILD-TO-SEVERE RHEUMATOID ARTHRITIS AFTER CONVENTIONAL DMARDS
    Wailoo, A. J.
    Stevenson, M.
    Tosh, J.
    Hernandez, M.
    Stevens, J. W.
    Archer, R.
    Simpson, E.
    Hock, Everson E.
    Scott, D.
    Young, A.
    Paisley, S.
    Williams, K.
    VALUE IN HEALTH, 2014, 17 (07) : A380 - A380
  • [24] The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers
    Yamasaki, Masaomi
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [25] Safety of tnf inhibitors and non-biologic DMARDs in rheumatoid arthritis patients previously treated with rituximab
    Emery, Paul
    Genovese, Mark C.
    Breedveld, Ferdinand
    Moreland, Larry
    Keystone, Edward
    Matteson, Eric L.
    Baptiste, Y.
    Reiss, William
    Sweetser, Marianne
    Shaw, Tim
    RHEUMATOLOGY, 2008, 47 : II48 - II49
  • [26] Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
    Choi, Se Rim
    Shin, Anna
    Ha, You-Jung
    Lee, Yun Jong
    Lee, Eun Bong
    Kang, Eun Ha
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 589 - 590
  • [27] RISK OF INFECTIONS BETWEEN JAK INHIBITORS AND TNF INHIBITORS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS
    Choi, S. R.
    Shin, A.
    Ha, Y. J.
    Lee, Y. J.
    Lee, E. B.
    Kang, E. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 716 - 716
  • [28] Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
    Riley, Thomas R.
    George, Michael D.
    RMD OPEN, 2021, 7 (01):
  • [29] Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics, and conventional synthetic DMARDs
    Ahn, S. S.
    Han, M.
    Jung, I.
    Kim, H. W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (09) : 1908 - 1916
  • [30] Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
    Rivera, Vijaya
    Sicsik Ayala, Sandra
    Vega Morales, David
    Irazoque-Palazuelos, Fedra
    Miranda Hernandez, Dafhne
    Casasola Vargas, Julio
    Carrillo Vazquez, Sandra
    Pena Ayala, Angelica
    Castillo Ortiz, Angel
    Munoz Monroy, Omar
    Duran Barragan, Sergio
    Paz Viscarra, Aleni
    Torres Valdez, Estefania
    Xibille Friedmann, Daniel
    Zamora Tehozol, Erick A.
    Valdes Corona, Luis
    Ramos Sanchez, Azucena
    Santana Portillo, Natalia
    Guerrero Diaz, Francisco
    Vazquez Zaragoza, Miguel
    Zepeda Moreno, Claudia
    Alvarado Sanchez, Kitzia
    Rivera Valencia, Melanea
    Pacheco Tena, Cesar
    Alpizar-Rodriguez, Deshire
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345